BUSCADOR RECOLECTA

Dataset includes two files: SI Tables, with five tables; and SI Figures, with eight figures., Information on international trade in octopus, cuttlefish and squid commodities for the period 2000-2019 downloaded from the UN COMTRADE database. The information is presented as tables with country rankings of the top five largest exporters and importers in volume and monetary terms over five-year periods. It also presents the top five flows in volume and monetary terms of octopus, cuttlefish and squid for the same periods. Additionally spatial explicit network graphs with different centrality measures and time periods are presented., Dolphinfish living in a warming ocean: How global climate change is reshaping the distribution, physiology and behaviour of marine migratory species and their associated fisheries. Co-tRiP. Funder: European Commission (EC) Grant number: 746361 “Vicenç Mut” postdoctoral fellowship 2020. Funder: Government of the Balearic Islands (Spain). Grant number: PD/002/2020 Xunta de Galicia Grupos de Referencia Competitiva. Funder: Government of Galicia (Spain). Grant number: ED431C2019/11) Grant for the RECREGES II project. Funder: Government of Galicia (Spain). Grant number: ED481B2018/017 Project: Cephs & Chefs – “Octopus, Squid, Cuttlefish, Sustainable Fisheries and Chefs". Funder: INTERREG Atlantic Area European funding programme. Grant number: EAPA 282/2016, Peer reviewed

Source data for plots in Fig. 2c,d., Peer reviewed

Source data for plots in Fig. 3c,d., Peer reviewed

Experimental data., Peer reviewed

Experimental data., Peer reviewed

Experimental data., Peer reviewed

(a) Young specimen of 2.7 cm diam., subumbrellar view. Arrow indicates the residual of the central mouth opening still open (scale bar = 0.25 cm). (b) As in (a), specimen 3 cm diam. (scale bar = 0.25 cm). (c) Subumbrellar view of a 4 cm diam. specimen, manubrium excised under the genital sinuses. Visible the four perradial canals projecting into the still wide central canal (scale bar = 0.25 cm). (d) Same view in a specimen of 5 cm diam., with the same pattern as in (c), but with a noticeable size reduction of the central quadrangular canal (scale bar = 0.25 cm). Black arrows in (c) and (d)indicate the edges of the perradial canals, white arrows indicate the central quadrangular canal., Peer reviewed

This Supplementary Material includes the ollowing sections: A)VITRIFAST: The Python Code of the Method to analyze the FSC data B)The parameters employed to analyze the examples showed in the main text C)Example of calorimetric curves with artificially-added noise D)Parameters employed to analyze the examples shown in the main text E)Examples of uncorrected data, Peer reviewed

(a) Specimen of 12.4 cm diam. with the juvenile central mouth closed (arrow) (scale bar = 1 cm). (b) oral arm of a specimen of 23.5 cm diam., showing the stained hemi-canal system on the right (arrows) and on the left the anastomosis that gives rise to the canals that reach both the inner wing (bottom left) and the outer ones (top)., Peer reviewed

Supplement Figure 1: ATRA treatment does not affect the viability of myeloma cell lines. MM.1S, OPM-2 and NCI-H929 cells were treated with ATRA for up to 72 hours. Cell viability was measured by flow cytometry and 7AAD staining (n=6). Bar diagrams show mean values +SD., Supplement Figure 2: ATRA plus crenigacestat treatment enhance BCMA expression on myeloma cell lines. Bar diagram shows BCMA expression on OPM-2 cells (n=3) after treatment with 100 nM ATRA and/or 10 nM GSI crenigacestat for 72 hours. Bar diagram shows mean values +SD. P-values between indicated groups were calculated using unpaired t-test. *p<0.05, **p<0.01., Supplement Figure 3: ATRA treatment leads to increased BCMA transcripts in OPM-2 myeloma cells. BCMA RNA levels in OPM-2 were analyzed by quantitative reverse transcription PCR (qRT-PCR) assay after incubation with increasing doses of ATRA for 48 hours (n=3). Bar diagram shows mean values +SD. P-values between indicated groups were calculated using unpaired t-test. *p<0.05., Supplement Figure 4: ATRA treatment leads to enhanced BCMA expression on primary myeloma cells. Representative flow cytometric analysis of BCMA expression on primary myeloma cells that had been cultured in the absence or presence of ATRA at different concentrations for 72 hours. 7-AAD was used to exclude dead cells from analysis., Supplement Figure 5: ATRA treatment does not impair viability of primary myeloma cells. Viability of primary myeloma cells with or without 72 hours of ATRA treatment was analyzed by flow cytometry and 7-AAD staining (n=5 biological replicates). Bar diagram shows mean values +SD., Supplement Figure 6: sBCMA does not impair BCMA CAR T cell functionality. CD8+ BCMA-CAR T-cells were co-cultured with MM.1S target cells in absence or presence of 150 ng/ml of soluble BCMA. After 4 hours, cytotoxicity was evaluated by bioluminescence- based assay. Diagram shows mean values +/-SD., Supplement Figure 7: ATRA treatment does not increase shedding of sBCMA. sBCMA concentration in the supernatant of OPM-2 and NCI-H929 after incubation with increasing doses of ATRA was analyzed by ELISA. Cell lines were cultured at 1x106/well (n=3 technical replicates). Bar diagrams show mean values +SD, P-values between indicated groups were calculated using 2way ANOVA. n.s. = not significant, *p<0.05, **p<0.01., Supplement Figure 8: BCMA-CAR T-cells confer enhanced cytotoxicity against ATRA plus crenigacestat-treated OPM-2 cells in vitro. OPM-2 cells were incubated with 100 nM ATRA and/or 10 nM GSI for 72 hours or were left untreated. Cytolytic activity of CD8+ BCMA- CAR T-cells was determined in a bioluminescence-based assay after 4h of co-incubation with target cells. Assay was performed in triplicate wells with 5,000 target cells per well. Data are presented as mean values +SD (n=4 biological replicates). P-values between indicated groups were calculated using unpaired t-test. n.s. = not significant, *p<0.05., Supplement Figure 9: Patient-derived BCMA-CAR T-cells confer enhanced cytotoxicity against ATRA-treated MM.1S cells. MM.1S cells were incubated with 50 nM ATRA for 72 hours or were left untreated. Cytolytic activity of MM patient-derived CD8+ BCMA-CAR T-cells was determined in a bioluminescence-based assay after 4h of co-incubation with target cells. Data are presented as mean values +SD of triplicate wells. P-values between indicated groups were calculated using unpaired t-test. *p<0.05, **p<0.01., Peer reviewed